Clinical Trial Update: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a chemotherapy-free combination of copanlisib (PI3K inhibitor) with obinutuzumab in previously untreated follicular lymphoma with high …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING